Research

Hormonal

Dual or triple agonists targeting GLP-1, GIP, and/or Glucagon receptors (GCGR) produce superior weight loss compared to selective GLP-1 receptor agonists alone.

Newer obesity medications that target multiple receptors (like GLP-1, GIP, and Glucagon) are more effective for weight loss than older single-target drugs. These include Tirzepatide and Retatrutide, which are approved or in advanced trials for obesity and diabetes.

GoodSupportsHIGH confidence
designing single peptides co-agonists at GLP-1R and GCGR may produce superior body weight benefits to GLP-1R agonism alone
Alessandro Pocai · Frontiers in Endocrinology · 2023

Why this rating

Supported by phase 2 trials and preclinical data, with some phase 3 trials ongoing.

Source

G protein-coupled receptors and obesity

Alessandro Pocai · Frontiers in Endocrinology · 2023

DOI 10.3389/fendo.2023.1301017

narrative_reviewCited 9×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →